Compare
Soligenix, Inc. vs Earth Science Tech, Inc. vs Can-Fite BioPharma Ltd. vs FibroBiologics, Inc.
| Latest fiscal year | Soligenix, Inc. SNGX | Earth Science Tech, Inc. ETST | Can-Fite BioPharma Ltd. CANF | FibroBiologics, Inc. FBLG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $35.70M | $405.0K | n/a |
| Revenue growth (YoY) | n/a | +7.8% | -39.9% | n/a |
| Gross margin | n/a | 71.4% | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | 10.2% | n/m | n/a |
| Net income | -$11.08M | $3.63M | -$9.83M | -$18.65M |
| EPS (Diluted) | -$2.14 | $0.012 | -$5.97 | -$0.42 |
| Operating cash flow | -$10.27M | $1.94M | -$8.95M | -$16.39M |
| Free cash flow | -$10.27M | $1.18M | -$8.95M | -$16.66M |
| Cash & equivalents | n/a | $796.8K | $5.53M | $4.89M |
| Total assets | $9.24M | $8.97M | $9.51M | $9.62M |
| Total liabilities | $3.94M | $1.93M | n/a | $3.46M |
| Shareholders' equity | $5.29M | $7.01M | $5.59M | $6.16M |
| Return on year-end equity | -209.4% | 51.8% | -175.8% | -302.9% |
| Shares outstanding | 10.09M | 291.32M | 2.62M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Soligenix, Inc. | Earth Science Tech, Inc. | Can-Fite BioPharma Ltd. | FibroBiologics, Inc. |
|---|---|---|---|---|
| Latest | $119.4K Ended 2024-12-31 | $35.70M Ended 2026-03-31 | $405.0K Ended 2025-12-31 | n/a |
| 1 year earlier | $839.4K Ended 2023-12-31 | $33.12M Ended 2025-03-31 | $674.0K Ended 2024-12-31 | n/a |
| 2 years earlier | $948.9K Ended 2022-12-31 | $11.95M Ended 2024-03-31 | $743.0K Ended 2023-12-31 | n/a |
| 3 years earlier | $824.3K Ended 2021-12-31 | $48.5K Ended 2023-03-31 | $810.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $2.36M Ended 2020-12-31 | $14.1K Ended 2022-03-31 | $853.0K Ended 2021-12-31 | n/a |